What is the association of renin-angiotensin-aldosterone system inhibitors with COVID-19 outcomes: retrospective study of racially diverse patients?

ABSTRACT:

Objective

To describe the clinical outcomes of COVID-19 in a racially diverse sample from the US Southeast and examine the association of renin-angiotensin-aldosterone system (RAAS) inhibitor use with COVID-19 outcome.

Design, setting, participants

This study is a retrospective cohort of 1024 patients with reverse-transcriptase PCR-confirmed COVID-19 infection, admitted to a 1242-bed teaching hospital in Alabama. Data on RAAS inhibitors use, demographics and comorbidities were extracted from hospital medical records.

Primary outcomes

In-hospital mortality, a need of intensive care unit, respiratory failure, defined as invasive mechanical ventilation (iMV) and 90-day same-hospital readmissions.

Results

Among 1024 patients (mean (SD) age, 57 (18.8) years), 532 (5

SUBMITTER: Khodneva Y 

PROVIDER: S-EPMC9006195 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature